These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 18651570)

  • 1. Replication competent Semliki Forest virus prolongs survival in experimental lung cancer.
    Määttä AM; Mäkinen K; Ketola A; Liimatainen T; Yongabi FN; Vähä-Koskela M; Pirinen R; Rautsi O; Pellinen R; Hinkkanen A; Wahlfors J
    Int J Cancer; 2008 Oct; 123(7):1704-11. PubMed ID: 18651570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of cancer virotherapy with attenuated replicative Semliki forest virus in different rodent tumor models.
    Määttä AM; Liimatainen T; Wahlfors T; Wirth T; Vähä-Koskela M; Jansson L; Valonen P; Häkkinen K; Rautsi O; Pellinen R; Mäkinen K; Hakumäki J; Hinkkanen A; Wahlfors J
    Int J Cancer; 2007 Aug; 121(4):863-70. PubMed ID: 17443493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic Semliki forest virus vector as a novel candidate against unresectable osteosarcoma.
    Ketola A; Hinkkanen A; Yongabi F; Furu P; Määttä AM; Liimatainen T; Pirinen R; Björn M; Hakkarainen T; Mäkinen K; Wahlfors J; Pellinen R
    Cancer Res; 2008 Oct; 68(20):8342-50. PubMed ID: 18922906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-Attenuated Clone of Virulent Semliki Forest Virus Overcomes Antiviral Type I Interferon in Resistant Mouse CT-2A Glioma.
    Martikainen M; Niittykoski M; von und zu Fraunberg M; Immonen A; Koponen S; van Geenen M; Vähä-Koskela M; Ylösmäki E; Jääskeläinen JE; Saksela K; Hinkkanen A
    J Virol; 2015 Oct; 89(20):10637-47. PubMed ID: 26269187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice.
    Vähä-Koskela MJ; Kallio JP; Jansson LC; Heikkilä JE; Zakhartchenko VA; Kallajoki MA; Kähäri VM; Hinkkanen AE
    Cancer Res; 2006 Jul; 66(14):7185-94. PubMed ID: 16849565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic herpes simplex virus treatment of metastatic breast cancer.
    Wang J; Hu P; Zeng M; Rabkin SD; Liu R
    Int J Oncol; 2012 Mar; 40(3):757-63. PubMed ID: 22108767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic alphavirus SFV-VA7 efficiently eradicates subcutaneous and orthotopic human prostate tumours in mice.
    Martikainen M; Ruotsalainen J; Tuomela J; Härkönen P; Essand M; Heikkilä J; Hinkkanen A
    Br J Cancer; 2017 Jun; 117(1):51-55. PubMed ID: 28557974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel genetically modified oncolytic vaccinia virus in experimental models is effective against a wide range of human cancers.
    Haddad D; Chen N; Zhang Q; Chen CH; Yu YA; Gonzalez L; Aguilar J; Li P; Wong J; Szalay AA; Fong Y
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S665-74. PubMed ID: 22258815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safe and Effective Treatment of Experimental Neuroblastoma and Glioblastoma Using Systemically Delivered Triple MicroRNA-Detargeted Oncolytic Semliki Forest Virus.
    Ramachandran M; Yu D; Dyczynski M; Baskaran S; Zhang L; Lulla A; Lulla V; Saul S; Nelander S; Dimberg A; Merits A; Leja-Jarblad J; Essand M
    Clin Cancer Res; 2017 Mar; 23(6):1519-1530. PubMed ID: 27637889
    [No Abstract]   [Full Text] [Related]  

  • 10. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
    Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
    Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.
    Lun XQ; Jang JH; Tang N; Deng H; Head R; Bell JC; Stojdl DF; Nutt CL; Senger DL; Forsyth PA; McCart JA
    Clin Cancer Res; 2009 Apr; 15(8):2777-88. PubMed ID: 19351762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity.
    Wildner O; Morris JC
    Cancer Res; 2000 Aug; 60(15):4167-74. PubMed ID: 10945625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors.
    Hakkarainen T; Särkioja M; Lehenkari P; Miettinen S; Ylikomi T; Suuronen R; Desmond RA; Kanerva A; Hemminki A
    Hum Gene Ther; 2007 Jul; 18(7):627-41. PubMed ID: 17604566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
    Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
    Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models.
    Ganesh S; Gonzalez-Edick M; Gibbons D; Van Roey M; Jooss K
    Clin Cancer Res; 2008 Jun; 14(12):3933-41. PubMed ID: 18559615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced therapeutic efficacy of oncolytic herpes vector G207 against human non-small cell lung cancer--expression of an RNA-binding protein, Musashi1, as a marker for the tailored gene therapy.
    Kanai R; Eguchi K; Takahashi M; Goldman S; Okano H; Kawase T; Yazaki T
    J Gene Med; 2006 Nov; 8(11):1329-40. PubMed ID: 16955534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel immunocompetent murine model for replicating oncolytic adenoviral therapy.
    Zhang L; Hedjran F; Larson C; Perez GL; Reid T
    Cancer Gene Ther; 2015 Jan; 22(1):17-22. PubMed ID: 25525035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus.
    Rein DT; Volkmer A; Beyer IM; Curiel DT; Janni W; Dragoi A; Hess AP; Maass N; Baldus SE; Bauerschmitz G; Breidenbach M
    Gynecol Oncol; 2011 Oct; 123(1):138-46. PubMed ID: 21741695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
    Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D
    Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of the tumor angiogenesis inhibitor bevacizumab and intratumoral oncolytic herpes virus injections as a treatment strategy for human gastric cancers.
    Deguchi T; Shikano T; Kasuya H; Nawa A; Fujiwara S; Takeda S; Gewen T; Sahin TT; Yamada S; Kanzaki A; Yamamura K; Fujii T; Sugimoto H; Nomoto S; Fukuda S; Nishikawa Y; Kodera Y; Nakao A
    Hepatogastroenterology; 2012 Sep; 59(118):1844-50. PubMed ID: 22172413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.